ArticleClinics (Sao Paulo, Brazil)
Differential characteristics and outcomes of women and men undergoing Impella-supported high-risk PCI: IMPELLA-PL registry.
Article in Clinics (Sao Paulo, Brazil). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImpella (Abiomed, Danvers, MA, USA) is a mechanical circulatory support device to prevent haemodynamic compromise in selected patients undergoing high-risk percutaneous coronary interventions.
objectivesData on sex differences in the setting of Impella-assisted high-risk percutaneous coronary interventions are limited. This analysis compared the characteristics and outcomes of women and men supported with Impella CP during high-risk percutaneous coronary interventions.
methodsConsecutive patients enrolled in the IMPELLA-PL registry, undergoing high-risk percutaneous coronary interventions from January 2014 until December 2021, with 12-month follow-up until December 2022, were included in the analysis. The main endpoints included (i) In-hospital mortality, (ii) Periprocedural complications, (iii) 12-month mortality, and major adverse cardiovascular events following hospital discharge.
resultsAmong 253 patients analyzed, women (12.6 %) were older (75.2 ± 7.7 years vs. 70.1 ± 10.0, p = 0.006), had more left main disease (81.2 % vs. 61.1 %, p = 0.043), and higher Syntax Score (46.0 vs. 42.5, p = 0.038). The in-hospital mortality rate was comparable between groups (9.4 % vs. 8.1 %, p = 0.736). Women experienced fewer device-related complications (6.3 % vs. 20.8 %, p = 0.049), but more systemic complications (68.8 % vs. 35.7 %, p < 0.001). Women trended towards lower 12-month mortality (9.4 % vs. 19.4 %, p = 0.053), while post-discharge major adverse cardiovascular events (15.6 % vs. 23.5 %, p = 0.439) were comparable.
conclusionsWomen and men undergoing Impella-assisted high-risk percutaneous coronary interventions have comparable in-hospital mortality rates, but different complication profiles. Following hospital discharge, the 12-month survival rate appears to be higher in women, despite more advanced age and a greater complexity of coronary artery disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.